Autolus Therapeutics plc
AUTLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAutolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. With a market capitalization of $409.9M, it sits in small-cap territory. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Market Cap
$409.9M
Beta
2.14
P/E (TTM)
—
P/E (Fwd)
-2.41
EPS (TTM)
$-1.11
EPS (Fwd)
$-0.64
ROE
-133.0%
ROA
-25.4%
Cash
$201.6M
Total Debt
$367.8M
Free CF
-$201.2M
52W Change
-6.7%
Annual Financials
Cash vs Debt
Where AUTL stands vs its 150-day and 200-day moving averages
As of the October 16, 2026 close, AUTL finished 0.58% above its 150-day moving average ($1.71) and 2.38% above its 200-day moving average ($1.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AUTL overbought or oversold?
At the October 16, 2026 close, AUTL's RSI(14) was 40.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, AUTL has $201.6M in cash with $367.8M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$201.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -133.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $6.2M (2022) to $75.4M (2025), reflecting a 1117% increase over the period.
A beta of 2.14 means AUTL is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Autolus Therapeutics plc and its sector.